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Background: Brain radiation necrosis (RN) occurring after radiotherapy is a serious complication. We and others
have performed several treatments for RN, using anticoagulants, corticosteroids, surgical resection and
bevacizumab. However, the mechanisms underlying RN have not yet been completely elucidated. For more than a
decade, platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) have been extensively studied in
many biological processes. These proteins influence a wide range of biological responses and participate in many
normal and pathological conditions. In this study, we demonstrated that PDGF isoforms (PDGF-A, B, C, and D) and
PDGFRs (PDGFR-α and β) are involved in the pathogenesis of human brain RN. We speculated on their roles, with a
focus on their potential involvement in angiogenesis and inflammation in RN.
Methods: Seven surgical specimens of RN, obtained from 2006 to 2013 at our department, were subjected to
histopathological analyses and stained with hematoxylin and eosin. We qualitatively analyzed the protein
expression of each isoform of PDGF by immunohistochemistry. We also examined their expression with double
immunofluorescence.
Results: All PDGFs were expressed in macrophages, microglia, and endothelial cells in the boundary of the core of
RN, namely, the perinecrotic area (PN), as well as in undamaged brain tissue (UB). PDGF-C, D and PDGFR-α were also
expressed in reactive astrocytes in PN. PDGFs and PDGFR-α were scarcely detected in UB, but PDGFR-β was
specifically expressed in endothelial cells not only in PN but also in UB.
Conclusions: PDGFs/PDGFRs play critical roles in angiogenesis and possibly in inflammation, and they contribute to
the pathogenesis of RN, irrespective of the original tumor pathology and applied radiation modality. Treatments for
the inhibition of PDGF-C, PDGF-D, and PDGFR-α may provide new approaches for the treatment of RN induced by
common radiation therapies.
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growth factor receptorsBackground
Higher radiation doses to tumors result in good local
tumor control and improvement in overall survival. On
the other hand, radiation necrosis (RN) in the brain oc-
curring after radiotherapy for brain tumors as well as for
head and neck cancers is a serious complication that de-
creases the quality of life in patients. The mechanisms
underlying RN have not been completely elucidated. In a* Correspondence: neu070@poh.osaka-med.ac.jp
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unless otherwise stated.previous study we showed that RN specimens stained with
hematoxylin and eosin (H&E) typically show marked
angiogenesis, so-called telangiectasis, microbleeding, and
interstitial edema, probably caused by leakage of plasma
from leaky angiogenesis into the surrounding necrotic
core—namely, the perinecrotic area (PN) [1].
We and others have applied several treatments for RN,
such as anticoagulants, vitamin E, corticosteroids, and sur-
gical resection [2-4]. The typical MRI of symptomatic RN
from case 3 demonstrated rapid shrinkage of the perile-
sional edema after surgical treatment [see Additional
file 1 and Table 1]. After surgical resection for the onlyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical features of patients with symptomatic radiation necrosis
Pt. Age (y) Sex Original dis. Radiationa Resection area (lobe) Durationb Chemo
1 46 F SCC. XRT (60 Gy), BNCT (13.9 Gy-Eq) Temporal 7 MTX
2 78 M Sal. Duc. Ca. XRT (60 Gy), BNCT (13.9 Gy-Eq) Frontotemporal 20 -
3 18 M GBM XRT (IMRT) (74 Gy) Parietal 37 -
4 63 F GBM XRT (24 Gy), BNCT (13 Gy-Eq) Frontoparietal 4 -
5 34 M GBM XRT (24 Gy), BNCT (13 Gy-Eq) Frontal 6 -
6 56 F GBM Proton + XRT (total 90 Gy) Temporoparietal 10 ACNU
7 46 F Ade. Ca. XRT (30 Gy), SRS (55 Gy, 65 Gy) Frontal 32 Herceptin
Pt, patient; y, year; F, female; M, male; Original dis, original disease; SCC, Squamous cell carcinoma; Sal. Duc. Ca, salivary ductal carcinoma; GBM, glioblastoma;
Ade. Ca, adenocarcinoma; XRT, X-ray radiation treatment; IMRT ,intensity modulated radiation therapy; BNCT, boron neutron capture therapy; Proton, proton beam
therapy; MTX, methotrexate; ACNU, nimustin; Herceptin, trastuzumab;
aIn Pt. 1 and 2, the temporal lobe was included in the irradiation field and in Pt. 3, 4, 5, and 6, local radiation therapy was administered. Pt. 7 had received whole
brain irradiation and received SRS twice. In BNCT, the presented dose is the peak point dose for the normal brain.
bMonths between termination of the last radiotherapy and onset of symptoms caused by radiation necrosis.
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compared with preoperative MRI. This rapid shrinkage of
the perilesional edema after surgical treatment was also
observed in other cases. In addition, bevacizumab, an anti-
body for vascular endothelial growth factor (VEGF), has
recently shown promising effects on symptomatic brain
RN and symptomatic pseudo-progression [5,6]. However,
in some cases, treatment with bevacizumab was not suffi-
cient to resolve RN. Some RN cases recurred as RN even
after temporary remission by bevacizumab treatment [7].
Recent experiments have shown that demyelination
and damage of the normal vasculatures and the appear-
ance of abnormal vasculatures around necrotic foci are
major issues in the development of RN [8,9]. In addition,
we previously reported that hypoxia-inducible factor 1α
(HIF-1α) and VEGF are key molecules in RN [1]. In a
later study, we tried to determine whether not only HIF-
1α and VEGF, but also proinflammatory cytokines such
as IL-1α, IL-6, TNF-α, and NFκB, might play significant
roles in RN, since these cytokines were produced by CD68-
and hGLUT5-positive microglia and/or macrophages ac-
cumulated in PN (in submission).
The platelet-derived growth factors (PDGFs) signaling
pathway, which has been extensively studied and shown
to play critical roles in many biological processes, is
mediated through tyrosine kinase receptors (PDGFR-α,
PDGFR-β) [10,11]. There are five members of the PDGF
family: PDGF-A, B, and AB, and the recently discovered
PDGF-C and D. So far, no heterodimers involving the
PDGF-C and D chains have been described. PDGF-A
binds only PDGFR-α, whereas PDGF-B activates PDGFR-α,
αβ, and β. PDGF-A, B, and C activate PDGFR-α and αβ,
while PDGF-D specifically binds to and activates its cognate
receptor PDGFR-β. In other words, according to published
data, PDGFR-α binds PDGF-A, B, AB, and C, whereas
PDGFR-β binds PDGF-B and D [10,12,13].
In addition, PDGF-A and B are secreted in their active
forms, while PDGF-C and D are secreted as inactive formsrequiring activation for their function [14]. Interestingly,
several reports have shown that the structure and bio-
logical function of PDGFs are quite similar to those of
VEGF [15]. Therefore, the PDGF family is sometimes re-
ferred to as the VEGF family. Nevertheless, in recent years
it was revealed that the angiogenic pathway induced by
PDGF-C is, in large part, VEGF-independent [16].
Based on these findings, in this retrospective study we
performed histopathological and immunohistochemi-
cal analyses on 7 human RN specimens from patients
who we had treated surgically from 2006 to 2013 at our
department. We here describe the findings common to
all 7 of these specimens, and demonstrate which type
of cells produce PDGFs and which type express the




Seven surgical specimens, obtained from 2006 to 2013,
were submitted for histopathological analysis, staining
with H&E, and immunohistochemistry. All the patients
had received radiotherapy, including X-ray treatment
(XRT), stereotactic radiosurgery (SRS), proton beam
therapy, and boron neutron capture therapy (BNCT).
The primary diseases were 4 glioblastomas, 2 head and
neck cancers, and 1 metastatic brain tumor derived from
breast cancer.
In this study we selected the area as radiation necrosis
with extensive necrotic area with the boundary of exten-
sive angiogenesis and edema, which is continuous to un-
damaged brain tissue, as mentioned in Background.
For the 2 patients with head and neck cancers, radio-
therapy was used to treat the parotid lesions and the
temporal lobe was included in the irradiation field.
Therefore, there were no tumor cells in the brain, indi-
cating pure brain RN. The patient characteristics are de-
tailed in Table 1.
Table 3 Double immunofluorescence combinations
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Histological and immunohistochemical analyses were per-
formed on paraffin sections in which we observed the
presence of RN by H&E staining. Each section was immu-
nostained with the following antibodies: PDGF-A (1:20;
R&D Systems, USA), PDGF-B (1:20; Abcam, Japan),
PDGF-C (1:100; R&D Systems), PDGF-D (1:50; R&D
Systems), PDGFR-α (1:20; R&D Systems), and PDGFR-β
(1:50; R&D Systems) (Table 2). We routinely use a pres-
sure cooker for 4 minutes to retrieve all the antigens. En-
dogenous peroxidase was blocked with 0.03% hydrogen
peroxide for 40 minutes at room temperature. We used
the ABC technique (Vector Laboratories, USA) for all of
these antigens, before DAB (3, 3′ diaminobenzidine tetra-
hydrochloride (Wako Pure Chemical Industries, Japan)).
The sections were counterstained with hematoxylin 3G
(Sakura Finetek, Japan) and mounted.
Immunofluorescence
Double immunofluorescence was performed using the
following antibody combinations: PDGF-C and GFAP (1:25;
Dako, Denmark), CD68 (1:25; Epitomics, USA), hGLUT5
(1:50; IBL, Japan), or CD45 (1:50; Epitomics); PDGF-D and
GFAP, CD68, hFLUT5, or CD45; PDGFR-α and GFAP,
CD68, hGLUT5, or CD31 (1:20; Dako, Denmark); and
PDGFR-β and GFAP, CD68, hGLUT5, or CD31.
GFAP, CD68, hGLUT5, CD45, and CD31 were adopted
as markers for astrocytes, monocytes, microglia, lympho-
cytes, and endothelial cells, respectively. All sections were
incubated with their respective antibodies for 24 hours
with CD68, hGLUT5, and GFAP, and for 48 hours with
PDGF-A, B, C, D, and PDGFR-α and β. Then, after
washing the primary antibodies, Alexa Fluor 488 (1:25;Table 2 List of primary antibodies used

















CD68 KP-1 Dako, Glostrup, Denmark m/m 1:25
hGLUT5 IBL, Tokyo, Japan p/r 1:50
GFAP 6 F2 Dako, Glostrup, Denmark m/m 1:25
CD45 EP322Y Eptomics, Burlingame, CA m/r 1:50
CD31 JC70A Dako, Glostrup, Denmark m/m 1:20
p/g polyclonal goat; p/r, polyclonal rabbit; m/r, monoclonal rabbit; m/m,
monoclonal mouse.Molecular Probes, USA) or Alexa Fluor 546 (1:25;
Molecular Probes) was used (Table 3). Finally, the sections
were examined using an LSM510 laser scanning confocal
microscope (Carl Zeiss, Germany).
Statistical analysis
We assessed the frequency of expression of PDGFs
semi-quantitatively by the following method. Five fields
of each PDGF isoform in which abnormal angiogenesis
was detected were randomly selected with a microscope.
PDGF-positive mononuclear cells were counted. We ob-
served 7 cases and, to reduce bias, used two observers to
count the cells. One observer, who was blinded to the
patients’ clinical and pathological information, evaluated
the results of immunohistochemical staining. The ratios
of PDGF-positive cells per total cells in each field were
calculated, and we statistically analyzed the data with
Steel-Dwass tests using JMP Pro 10 (SAS Institute,
USA). The results revealed that PDGF-C and D showed
higher frequency of expression than PDGF-A and B in
PN. The difference was statistically significant.
Ethical approval
This study was approved by an institutional committee
of Osaka Medical College. The research was in compli-
ance with the Helsinki Declaration.
Results
Expression of PDGFs
Figure 1 shows the results of H&E staining and immunohis-
tochemistry from case 1. H&E staining revealed a necroticPrimary Dilution Secondary Primary Dilution Secondary
PDGF-C 1:50 F488 CD68 1:25 F546
PDGF-C 1:50 F488 hGLUT5 1:50 F546
PDGF-C 1:50 F488 GFAP 1:25 F546
PDGF-C 1:50 F488 CD45 1:50 F546
PDGF-D 1:20 F488 CD68 1:25 F546
PDGF-D 1:20 F488 hGLUT5 1:50 F546
PDGF-D 1:20 F488 GFAP 1:25 F546
PDGF-D 1:20 F488 CD45 1:50 F546
PDGFR-α 1:10 F488 CD68 1:25 F546
PDGFR-α 1:10 F488 hGLUT5 1:50 F546
PDGFR-α 1:10 F488 GFAP 1:25 F546
PDGFR-α 1:10 F488 CD31 1:20 F546
PDGFR-β 1:20 F488 CD68 1:25 F546
PDGFR-β 1:20 F488 hGLUT5 1:50 F546
PDGFR-β 1:20 F488 GFAP 1:25 F546
PDGFR-β 1:20 F488 CD31 1:20 F546
Primary, primary antibody; Secondary, secondary antibody; F488, Alexa Fluor
488; F546, Alexa Fluor 546.
Figure 1 Results of hematoxylin and eosin staining (H&E) and immunohistochemistry from case 1. H&E staining (A) revealed a necrotic
core (NC) and perinecrotic area (PN), including micro bleeding (A, arrowhead) and abnormal angiogenesis (A, arrow). Immunostaining results for
PDGF-C are presented as a representative example (B). PDGF-C (C and D), D (E and F) and PDGFR-α (G) were produced by monocytic cells
(C, E, G, arrow) and reactive astrocytic cells (D, F, G, arrowhead) in PN. On the other hand, PDGFR-β (H and I) was expressed mainly in endothelial
cells (H and I*). There was partially nonspecific staining in NC (B) or around blood vessels (I). Original magnification, A, B and H × 40, C, D, E, F,
G and I × 200.
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which micro bleeding (Figure 1A. arrowhead) and abnor-
mal angiogenesis (Figure 1A. arrow) were confirmed.
PDGF-A, B, C, and D-positive cells were detected in PN.
The results of immunostaining for PDGF-C are shown as
a typical example of these distribution analyses (Figure 1B,
C, D). Morphologically, PDGF-A and B were produced by
some monocytic cells [see Additional file 2] in PN. On the
other hand, PDGF-C and D (Figure 1E, F) were produced
by many monocytic cells (arrows in Figure 1C, E), reactive
astrocytic cells (arrowheads in Figure 1D, F), and endothe-
lial cells (Figure 1D*). PDGF-A, B, C, and D were scarcely
detectable in UB (Figure 2).
These relationships among the expression of PDGFs
are summarized in Table 4. These relationships were also
confirmed with other specimens [see Additional file 3].
Our statistical analysis revealed that PDGF-C and D
showed higher frequencies of expression than PDGF-A
and B in PN. The difference was statistically significant
(p < 0.0001, Steel-Dwass test) (Figure 3). We also grouped
the cases into a GBM group (cases 3, 4, 5, 6) and non-
GBM group (cases 1, 2, 7) and analyzed the differences in
protein expression between them. No statistically signifi-
cant differences in the expression of any of the isoforms
were observed between the two groups by the Steel-Dwass
test [see Additional file 4]. Therefore, we considered thatthese primary diseases did not affect the expression of
PDGFs.
Double immunofluorescence from case 1 revealed that
PDGF-C or D-positive cells were merged with many cells
positive for CD68 (Figure 4A, E), GFAP (Figure 4B, F),
hGLUT5 (Figure 4C, G), and CD45 (Figure 4D, H).
H&E staining, immunohistochemistry, and double im-
munofluorescence also showed similar tendencies in other
specimens with symptomatic RN [see Additional files 3,
and 5].
Expression of PDGFRs
PDGFR-α was expressed in endothelial cells (Figure 1G*),
monocytic cells (Figure 1G arrow), and reactive astro-
cytic cells (Figure 1G, arrowhead) in PN. PDGFR-β was
expressed mainly in endothelial cells (Figure 1H, I*).
PDGFR-α was not expressed in any types of cells in UB
(Figure 2E), but PDGFR-β was detected in endothelial
cells in both PN and UB (Figure 2F).
Double immunofluorescence revealed that PDGFR-α
and β were strongly expressed in CD31-positive cells
(Figure 5D, I). PDGFR-β-positive cells were merged specif-
ically with endothelial cells (Figure 5F, G, H, I and J, *),
but PDGFR-α-positive cells were merged with cells posi-
tive for CD68 (Figure 5A), GFAP (Figure 5B), hGLUT5
(Figure 5C), and CD45 (Figure 5E) in PN.
Figure 2 Representative results of immunostaining of undamaged brain tissue (UB). PDGF-A, B, C, D and PDGFR-α were scarcely detectable
in UB (A through E). PDGFR-β (F) was specifically expressed in endothelial cells in UB. Many normal cerebral blood vessels stained with PDGFR-β
(F *) were detected in UB. Original magnification, ×200.
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specimens with symptomatic RN [see Additional file 6].
Double immunofluorescence revealed partially non-
specific staining, especially in endothelial cells (Figures 4,
and 5*). In cases where immunofluorescence was per-
formed with GFAP alone, vascular endothelial cells were
not stained [see Additional file 7]. These findings were
also observed in other specimens.
Discussion
PDGFs are a group of multifunctional proteins with a
wide variety of effects. They have important physiologic
functions in embryonic and organ development, have
been implicated in a wide variety of pathological pro-
cesses, including proliferation, differentiation, and fibro-
genesis, and are essential for the stability of normal blood
vessel formation [16-19]. However, the overexpression ofTable 4 Expression of PDGFs/PDGFRs in two areas of
the brain
UB PN
Mono Astro Endo Mono Astro Endo
PDGF-A - - - + - +
PDGF-B - - - + - +
PDGF-C - - - + + +
PDGF-D - - - + + +
PDGFR-α - - - + + +
PDGFR-β - - + - - +
UB, undamaged brain area; PN, perinecrotic area; Mono, monocytes, including
macrophages, microglia and lymphocytes Astro, reactive astrocytes; Endo,
endothelial cells ; -, not expressed; +, expressed.
Figure 3 Frequency of expression. We assessed the frequency of
expression of PDGFs semi-quantitatively by the following method.
Five fields of each PDGF isoform, in which abnormal angiogenesis
were detected, were randomly selected with a microscope. The
PDGF-positive mononuclear cells were counted. We observed all
7 cases and performed the counting using two observers to
reduce bias. One observer, who was blind to the patients’ clinical
and pathological information, evaluated the results of the
immunohistochemical staining. The ratios of PDGF-positive cells
to total cells in each field were calculated and were statistically
analyzed using Steel-Dwass tests with JMP Pro 10 (SAS Institute Inc.,
Cary, NC, USA). Statistical analysis revealed that PDGF-C and D showed
higher frequency of expression in the PN specimens than did PDGF-A
and B. The difference was statistically significant (*p < 0.0001,
Steel-Dwass test).
Figure 4 Double immunofluorescence staining. The results of double immunofluorescence staining from case 1 revealed that PDGF-C or
D-positive cells were merged with many CD68 (A, E), GFAP (B, F), hGLUT5 (C, G), and CD45 (D, H) -positive cells in PN. Some PDGF-C or
D-positive cells did not express CD68, GFAP, hGLUT5 or CD45 and vice versa. Endothelial cells (*) were nonspecifically stained with secondary
fluorescence antibody. The scale bar represents 50 μm.
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demonstrated that various cell types, including macro-
phages, fibroblasts, pericytes, and capillary endothelial cells,
express PDGFs [20,21]. Deuel et al. also reported that a
macrophage-derived PDGF induces chemotaxis and the
proliferation of monocytes and fibroblasts during inflam-
mation and wound repair [22].
This is the first study to explore the expression of
PDGF isoforms and PDGFRs in human brain RN. Our
results have shown that all PDGFs and PDGFRs were
expressed in brain RN, and that PDGFs and PDGFRα
were primarily expressed by macrophages, microglia, re-
active astrocytes, lymphocytes, and endothelial cells in
PN. These findings suggest that the activation of PDGFs
is coincident with inflammation, angiogenesis, and fibro-
genesis in the pathophysiology of RN.
Our recent study revealed that CD45-positive lympho-
cytes expressing CXCR4 might be drawn into PN from
peripheral blood by chemotaxis, but they do not express
proinflammatory cytokines, and their roles in RN remain
unclear (submitted for publication). However, in the present
study, CD45-positive lymphocytes produced PDGF-C
and -D. These results suggest that CD45-positive lympho-
cytes in PN do not produce proinflammatory cytokines
but may play significant indirect roles in angiogenesis
and/or inflammation.The highest differences of expression among PDGFs
on brain RN were observed in PDGF-C and D (Figure 3
and Additional file 4). In this study, the expressions of
PDGF-C and D were significantly higher than the expres-
sions of PDGF-A and B in PN. Our current immunohisto-
chemical study has further revealed that inflammatory
cells, including macrophages, microglia, and even lympho-
cytes, were gathered in PN and produced PDGF-C and D.
These mononuclear cells are known to play important
roles in wound healing and inflammatory disease by pro-
ducing a variety of growth factors and cytokines [23,24].
In our recent study, these mononuclear cells produced in-
flammatory cytokines (IL-1α, IL-6, TNF-α, NFκB) (sub-
mitted for publication). In the present study, these cells
also produced PDGF-C and D. Therefore the activation of
PDGF-C and D is coincident with inflammation as well as
angiogenesis. These findings suggest that PDGF-C and D
are involved in multiple aspects of brain RN.
The present and previous reports have revealed that
the differential expression of PDGFs has also been seen
in pathological conditions other than RN. In the aortic
ring outgrowth assay, PDGF-C mediated significantly in-
creased outgrowth, comparable to the levels mediated by
VEGF and PDGF-A and B [25]. The angiogenic activity
of PDGF-C in vivo is more potent than that of PDGF-A,
AB or B [26]. PDGF-D also has been shown to stimulate
Figure 5 Double immunofluorescence staining. Double immunofluorescence staining from case 1 revealed that PDGFR-α and β were strongly
expressed in CD31-positive cells in PN (D and I). PDGFR-α positive cells were merged with many cells positive for CD68 (A), GFAP (B), hGLUT5
(C), and CD45 (E). PDGFR-β-positive cells merged specifically with endothelial cells (F, G, H, I and J, *). Endothelial cells (*) were nonspecifically
stained with secondary fluorescence antibody. The scale bar represents 50 μm.
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[21,27,28].
Li et al. found that PDGF-D is a potent transforming
and angiogenic growth factor for NIH/3 T3 cells, and
that the transformed cells also induce VEGF expression
[28]. Zhao et al. also found that inhibition of PDGF-D
leads to decreased cell invasion in gastric cancer, partly
through the regulation of VEGF [29]. In our study, many
reactive astrocytes produced PDGF-C and D and expressed
PDGFR-α, but these cells did not express PDGFR-β. These
results established that PDGF-C and D play roles in angio-
genesis and inflammation through autocrine and paracrine
stimulation. Although the functions of these isoforms of
PDGFs on cells are similar in many respects, each isoformmight play different roles in different cell types via various
receptors and pathways.
Previously, it was reported that several types of cells
participate in angiogenesis and inflammation in brain
RN [1,5,6]. But the underlying mechanisms have not been
completely elucidated. We desperately need to know why
different types of cells, including macrophages, microglia,
lymphocytes, and astrocytes, acquire the capacity for
differentiation, producing inflammatory cytokines and
growth factors under certain pathological conditions.
Ungvari et al. reported that γ-irradiated cerebromicrovas-
cular endothelial cells acquired a senescence-associated
secretory phenotype (SASP) characterized by the upregu-
lation of proinflammatory cytokines and chemokines [30].
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irradiation in PN acquired SASP, and that this mechanism
may be a key process in brain RN.
In this study, we performed retrospective analysis with
clinical specimens of symptomatic RN and revealed that
PDGFs/PSGFRs were involved in RN. However, this ana-
lysis covers just one aspect of RN. It is impossible to de-
termine whether PDGFs exacerbate RN or rather are
produced as a byproduct of RN. Also, we cannot specu-
late as to the dose–response relationship or the time
course of the expression of PDGFs and their receptors
in RN. These questions will be answered if a reprodu-
cible animal model of RN can be established.
Conclusions
In conclusion, PDGFs/PDGFRs play critical roles in angio-
genesis and possibly in inflammation, and they contribute
to the pathogenesis of RN, irrespective of the original
tumor pathology and applied radiation modality. More-
over, the autocrine or paracrine signaling of PDGFs also
plays crucial roles in aggressive angiogenesis and inflam-
mation in RN. PDGF-C, PDGF-D and PDGFR-α have
clinical importance, because PDGFR-β was expressed even
in UB. Treatments to inhibit PDGF-C and D, or to inhibit
PDGF-C and D in combination with PDGFR-α with a kin-
ase inhibitor, may provide new approaches for RN induced
by common radiation therapies, including XRT, SRS and
BNCT.Additional files
Additional file 1: Typical MRI of symptomatic radiation necrosis
from case 3. Gd-enhanced T1 MRI just prior to excision of necrotic foci
(A). Gd-enhanced T1 MRI 2 weeks after surgery (A’). FLAIR MRI just prior
to excision of necrotic foci (B). FLAIR MRI, 2 weeks after surgery (B’). After
surgical resection of the only enhanced lesion, perilesional edema was
decreased compared with preoperative MRI.
Additional file 2: Representative immunohistochemistry from
case 1. Immunostaining revealed the necrotic core (A, D NC) and
perinecrotic area (A, D PN). PDGF-A (A, B, C) and PDGF-B (D, E) were
produced by some monocytic cells (B, E arrow) and endothelial cells
(C, E*) in PN. Original magnification, A, D × 40, B, C, E × 200.
Additional file 3: H&E staining and immunohistochemistry from
case 3. H&E staining (A) and immunohistochemistry (B through O) from
case 3, showing NC and PN. PDGF-A (B, C) and PDGF-B (D, E) were
produced by some monocytic cells (arrows in C, E) in PN. In contrast,
PDGF-C (F, G, H) and PDGF-D (I, J) were produced by many monocytic
cells (arrows in G, H, J), reactive astrocytic cells (arrowheads in G, J), and
endothelial cells (H, J*). PDGFR-α (K, L, M) was expressed in monocytic
cells (L, arrow), reactive astrocytic cells (L, arrowhead) and endothelial
cells (M*) in PN. PDGFR-β (N, O) was expressed mainly in endothelial cells
(O*). Original magnification, A, B, D, F, I, K, N × 40, C, E, G, H, J, L, M,
O × 200.
Additional file 4: Frequency of expression of PDGFs in the GBM
group and non-GBM group. We assessed the frequency of expression
of PDGFs semi-quantitatively. In the GBM group (cases 3, 4, 5, 6) and
non-GBM group (cases 1, 2, 7), there was no apparent statistical
significance in expression of each isoform (A, B, C, D).Additional file 5: Double immunofluorescence staining results from
case 3. Double immunofluorescence staining from case 3 revealed that
PDGF-C or D-positive cells were merged with many CD68, hGLUT5, CD45
and GFAP-positive cells. Endothelial cells (*) were nonspecifically stained
with secondary fluorescence antibody. The scale bar represents 50 μm.
Additional file 6: Double immunofluorescence staining results from
case 3. Double immunofluorescence staining of the specimen from case
3 revealed that PDGFR-α and β were strongly expressed in CD31-positive
cells (D and I). PDGFR-α-positive cells were merged with many cells positive
for CD68 (A), GFAP (B), hGLUT5 (C), and CD45 (E). PDGFR-β-positive cells
were merged specifically with endothelial cells (F thorough J). Endothelial
cells (*) were nonspecifically stained with secondary fluorescence antibody.
The scale bar represents 50 μm.
Additional file 7: Immunofluorescence staining from consecutive
specimens from case 1 and 3. Immunofluorescence staining of
consecutive specimens from case 1 (A, B) and 3 (C, D) showed positivity for
PDGFR-β (A) or GFAP (B). PDGFR-β (A) was not observable at an excitation
wavelength of 561 nm but was apparent at 499 nm in endothelial cells (*).
On the other hand, GFAP (B) was observed only at an excitation wavelength
of 561 nm in reactive astrocytes. The scale bar represents 50 μm.
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